ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Interestingly, BOR and PSI targeted the BCR-ABL oncoprotein and induced apoptosis of CML cells sensitive or resistant to IM, and exerted synergic effects with histone deacetylase inhibitors and cyclin-dependent kinase inhibitor flavopiridol [22]–[26].